Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients

International Journal of Cardiology

Volumn 165, Issue 1, 2013, Pages 204-206

  Wu, Hongyi ^a   Qian, Juying ^a   Xu, Jianfeng ^b   Sun, Aijun ^a   Sun, Wenzhu ^c   Wang, Qibing ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Clopidogrel; CYP2C19; Pharmacogenetics; Platelet reactivity; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19; PROTON PUMP INHIBITOR;

ADULT; ALLELE; CHINESE; CONTROLLED STUDY; CYP2C19 GENE; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LETTER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PLATELET REACTIVITY; PON1 GENE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; ACUTE CORONARY SYNDROME; AGE; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; GENDER; GENETIC ASSOCIATION; GENOTYPE; HYPERTENSION; LOSS OF FUNCTION MUTATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT DURATION;

EID: 84876148773     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.08.017     Document Type: Article

References (8)

1. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
2. D.R. Holmes Jr., G.J. Dehmer, and S. Kaul ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Circulation 122 2010 537 557
3. H.J. Bouman, E. Schömig, and J.W. van Werkum Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 1 2011 110 116
4. J.S. Hulot, J.P. Collet, and G. Cayla CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients Circ Cardiovasc Interv 4 5 2011 422 428
5. T. Simon, P.G. Steg, and L. Becquemont Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction Clin Pharmacol Ther 90 4 2011 561 567
6. D. Sibbing, W. Koch, and S. Massberg No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 13 2011 Jul 1605 1613
7. J.P. Lewis, A.S. Fisch, and K. Ryan Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response Clin Pharmacol Ther 90 4 2011 568 574
8. K.P. Bliden, J. DiChiara, and U.S. Tantry Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 6 2007 657 666